Browse TGFBR3

Summary
SymbolTGFBR3
Nametransforming growth factor, beta receptor III
Aliases betaglycan; BGCAN; betaglycan proteoglycan; transforming growth factor, beta receptor III (betaglycan, 300kD ......
Chromosomal Location1p33-p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted. Secreted, extracellular space. Cell membrane Single-pass type I membrane protein Note=Exists both as a membrane-bound form and as soluble form in serum and in the extracellular matrix.
Domain PF00100 Zona pellucida-like domain
Function

Binds to TGF-beta. Could be involved in capturing and retaining TGF-beta for presentation to the signaling receptors.

> Gene Ontology
 
Biological Process GO:0001570 vasculogenesis
GO:0001666 response to hypoxia
GO:0001837 epithelial to mesenchymal transition
GO:0001889 liver development
GO:0002262 myeloid cell homeostasis
GO:0003007 heart morphogenesis
GO:0003150 muscular septum morphogenesis
GO:0003151 outflow tract morphogenesis
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003208 cardiac ventricle morphogenesis
GO:0003223 ventricular compact myocardium morphogenesis
GO:0003229 ventricular cardiac muscle tissue development
GO:0003231 cardiac ventricle development
GO:0003279 cardiac septum development
GO:0003281 ventricular septum development
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007181 transforming growth factor beta receptor complex assembly
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0014706 striated muscle tissue development
GO:0014855 striated muscle cell proliferation
GO:0016049 cell growth
GO:0016202 regulation of striated muscle tissue development
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0030099 myeloid cell differentiation
GO:0030218 erythrocyte differentiation
GO:0030509 BMP signaling pathway
GO:0030511 positive regulation of transforming growth factor beta receptor signaling pathway
GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0032354 response to follicle-stimulating hormone
GO:0033002 muscle cell proliferation
GO:0034101 erythrocyte homeostasis
GO:0034694 response to prostaglandin
GO:0034695 response to prostaglandin E
GO:0034698 response to gonadotropin
GO:0034699 response to luteinizing hormone
GO:0035051 cardiocyte differentiation
GO:0035265 organ growth
GO:0036293 response to decreased oxygen levels
GO:0043393 regulation of protein binding
GO:0045844 positive regulation of striated muscle tissue development
GO:0045927 positive regulation of growth
GO:0046620 regulation of organ growth
GO:0046622 positive regulation of organ growth
GO:0048514 blood vessel morphogenesis
GO:0048634 regulation of muscle organ development
GO:0048636 positive regulation of muscle organ development
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048644 muscle organ morphogenesis
GO:0048732 gland development
GO:0048738 cardiac muscle tissue development
GO:0048762 mesenchymal cell differentiation
GO:0048872 homeostasis of number of cells
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0051098 regulation of binding
GO:0051271 negative regulation of cellular component movement
GO:0055006 cardiac cell development
GO:0055008 cardiac muscle tissue morphogenesis
GO:0055010 ventricular cardiac muscle tissue morphogenesis
GO:0055017 cardiac muscle tissue growth
GO:0055021 regulation of cardiac muscle tissue growth
GO:0055023 positive regulation of cardiac muscle tissue growth
GO:0055024 regulation of cardiac muscle tissue development
GO:0055025 positive regulation of cardiac muscle tissue development
GO:0060021 palate development
GO:0060038 cardiac muscle cell proliferation
GO:0060043 regulation of cardiac muscle cell proliferation
GO:0060045 positive regulation of cardiac muscle cell proliferation
GO:0060216 definitive hemopoiesis
GO:0060317 cardiac epithelial to mesenchymal transition
GO:0060318 definitive erythrocyte differentiation
GO:0060343 trabecula formation
GO:0060347 heart trabecula formation
GO:0060389 pathway-restricted SMAD protein phosphorylation
GO:0060411 cardiac septum morphogenesis
GO:0060412 ventricular septum morphogenesis
GO:0060415 muscle tissue morphogenesis
GO:0060419 heart growth
GO:0060420 regulation of heart growth
GO:0060421 positive regulation of heart growth
GO:0060485 mesenchyme development
GO:0060537 muscle tissue development
GO:0060935 cardiac fibroblast cell differentiation
GO:0060936 cardiac fibroblast cell development
GO:0060938 epicardium-derived cardiac fibroblast cell differentiation
GO:0060939 epicardium-derived cardiac fibroblast cell development
GO:0060976 coronary vasculature development
GO:0060977 coronary vasculature morphogenesis
GO:0060979 vasculogenesis involved in coronary vascular morphogenesis
GO:0061008 hepaticobiliary system development
GO:0061383 trabecula morphogenesis
GO:0061384 heart trabecula morphogenesis
GO:0070482 response to oxygen levels
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:1901654 response to ketone
GO:1901861 regulation of muscle tissue development
GO:1901863 positive regulation of muscle tissue development
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus
GO:1903846 positive regulation of cellular response to transforming growth factor beta stimulus
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004675 transmembrane receptor protein serine/threonine kinase activity
GO:0005024 transforming growth factor beta-activated receptor activity
GO:0005114 type II transforming growth factor beta receptor binding
GO:0005126 cytokine receptor binding
GO:0005160 transforming growth factor beta receptor binding
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0015026 coreceptor activity
GO:0017134 fibroblast growth factor binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0019838 growth factor binding
GO:0019955 cytokine binding
GO:0030165 PDZ domain binding
GO:0046332 SMAD binding
GO:0048185 activin binding
GO:0050431 transforming growth factor beta binding
GO:0070123 transforming growth factor beta receptor activity, type III
GO:1901681 sulfur compound binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0009897 external side of plasma membrane
GO:0034673 inhibin-betaglycan-ActRII complex
GO:0043235 receptor complex
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTGFBR3
Nametransforming growth factor, beta receptor III
Aliases betaglycan; BGCAN; betaglycan proteoglycan; transforming growth factor, beta receptor III (betaglycan, 300kD ......
Chromosomal Location1p33-p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TGFBR3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TGFBR3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23925295Breast Carcinoma; MelanomaPromote immunityUsing murine models of breast cancer and melanoma, we elucidated a tumor immunoevasion mechanism whereby loss of tumor-expressed TGFBR3/sTGFBR3 enhanced TGF-β signaling within locoregional DC populations and upregulated both the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DCs and the CCL22 chemokine in myeloid DCs. Alterations in these DC populations mediated Treg infiltration and the suppression of antitumor immunity.
Summary
SymbolTGFBR3
Nametransforming growth factor, beta receptor III
Aliases betaglycan; BGCAN; betaglycan proteoglycan; transforming growth factor, beta receptor III (betaglycan, 300kD ......
Chromosomal Location1p33-p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TGFBR3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTGFBR3
Nametransforming growth factor, beta receptor III
Aliases betaglycan; BGCAN; betaglycan proteoglycan; transforming growth factor, beta receptor III (betaglycan, 300kD ......
Chromosomal Location1p33-p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TGFBR3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8420.0212
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9310.519
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7890.385
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1690.774
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0690.976
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4650.865
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0510.879
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1690.91
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3010.857
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4730.59
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3570.241
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.150.432
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TGFBR3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTGFBR3
Nametransforming growth factor, beta receptor III
Aliases betaglycan; BGCAN; betaglycan proteoglycan; transforming growth factor, beta receptor III (betaglycan, 300kD ......
Chromosomal Location1p33-p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TGFBR3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTGFBR3
Nametransforming growth factor, beta receptor III
Aliases betaglycan; BGCAN; betaglycan proteoglycan; transforming growth factor, beta receptor III (betaglycan, 300kD ......
Chromosomal Location1p33-p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TGFBR3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TGFBR3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTGFBR3
Nametransforming growth factor, beta receptor III
Aliases betaglycan; BGCAN; betaglycan proteoglycan; transforming growth factor, beta receptor III (betaglycan, 300kD ......
Chromosomal Location1p33-p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TGFBR3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTGFBR3
Nametransforming growth factor, beta receptor III
Aliases betaglycan; BGCAN; betaglycan proteoglycan; transforming growth factor, beta receptor III (betaglycan, 300kD ......
Chromosomal Location1p33-p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TGFBR3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTGFBR3
Nametransforming growth factor, beta receptor III
Aliases betaglycan; BGCAN; betaglycan proteoglycan; transforming growth factor, beta receptor III (betaglycan, 300kD ......
Chromosomal Location1p33-p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TGFBR3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTGFBR3
Nametransforming growth factor, beta receptor III
Aliases betaglycan; BGCAN; betaglycan proteoglycan; transforming growth factor, beta receptor III (betaglycan, 300kD ......
Chromosomal Location1p33-p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TGFBR3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.